A major burden on patient quality of life and the healthcare system in the U.S., heart failure (HF) is associated with high morbidity and mortality rates. Despite the use of guideline-directed medical therapy (GDMT), many HF patients may experience worsening symptoms and disease progression. Barostim is a novel device therapy that works with GDMT and targets the neurohormonal pathways responsible for HF progression and symptoms. Join this webinar to learn more about how Barostim can help your HF patients.

Bonnie Handke, Senior Vice President of Patient Access
Jim Kreiner, MHA, Director, Cardiovascular Operations, Prisma Heart Hospital
Dr. Patrick McCann, Physician, Prisma Heart Hospital